Valuation : Tsubota Laboratory Incorporated

Market Cap 7.48B 46.76M 40.29M 37.78M 34.49M 64.97M 4.47B 65.17M 448M 175M 2.26B 176M 172M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 6.58B 41.13M 35.44M 33.23M 30.33M 57.14M 3.93B 57.32M 394M 154M 1.98B 154M 151M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
Aug. 11 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
Jun. 16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
May. 31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
May. 31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
May. 15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
May. 15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
Feb. 13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
Feb. 13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
25-05-11 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
25-02-17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
24-11-20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
22-12-18 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
22-09-19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
Manager TitleAgeSince
President 71 2019-01-31
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 2024-12-31
Director TitleAgeSince
Director/Board Member 71 2019-01-31
Director/Board Member 70 2020-05-31
Director/Board Member 55 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 46.96M
-0.78%-1.42%+2.49%+22.78% 51.14B
-5.76%-0.80%+442.17%+544.09% 47.4B
-0.05%+0.73%+38.67%+18.00% 43.19B
-1.57%-2.20%+22.91%+81.22% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-1.36%-2.78%+27.61%+130.65% 17.07B
-1.01%-2.41% - - 16.38B
-0.88%-0.66%+11.60%+27.75% 14.76B
-1.41%-1.11%+78.84%+46.86% 14.15B
Average -1.30%+0.70%+80.19%+115.47% 31.07B
Weighted average by Cap. -1.64%+1.12%+98.97%+137.55%

Financials

2025 2026
Net sales 1.36B 8.48M 7.31M 6.85M 6.26M 11.79M 811M 11.82M 81.31M 31.72M 409M 31.85M 31.16M 200M 1.25M 1.08M 1.01M 922K 1.74M 119M 1.74M 11.98M 4.68M 60.32M 4.69M 4.59M
Net income 205M 1.28M 1.1M 1.04M 945K 1.78M 122M 1.79M 12.28M 4.79M 61.82M 4.81M 4.71M -761M -4.76M -4.1M -3.84M -3.51M -6.61M -455M -6.63M -45.6M -17.79M -230M -17.86M -17.47M
Net Debt -1.45B -9.05M -7.8M -7.31M -6.68M -12.58M -865M -12.62M -86.76M -33.85M -437M -33.98M -33.24M -901M -5.63M -4.85M -4.55M -4.15M -7.83M -538M -7.85M -53.99M -21.06M -272M -21.15M -20.69M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-